MKMaria Koltowska-Häggström

Maria Koltowska-Häggström

*This is an algorithmically generated author record based on publicly available information.

Maria Koltowska-Häggström has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The cost-effectiveness of growth hormone replacement therapy (Genotropin®) in hypopituitary adults in Sweden

    by Kristian Bolin, Rickard Sandin, Maria Koltowska-Häggström, Jane Loftus, Christin Prütz, Björn Jonsson

    To evaluate the cost-effectiveness of growth hormone (GH) treatment (Genotropin®) compared with no GH treatment in adults with GH deficiency in a Swedish societal setting.


  • GH deficiency during the transition period: clinical characteristics before and after GH replacement therapy in two different subgroups of patients

    by Hugo L. Fideleff, Björn Jonsson, Maria Koltowska-Häggström, Margaret C.S. Boguszewski, Patrick Wilton, Hugo R. Boquete

    To study two subsets of patients with GH deficiency (GHD) during the transition period: childhood onset GHD (CO-GHD) and patients who develop GHD during the transition phase (TO-GHD) before and after GH replacement. In 1340 GHD subjects from KIMS (Pfizer International Metabolic Database), CO (n=586) or TO (n=754), background characteristics, anthropometric measurements, IGF-1, lipids and quality of life (QoL) were evaluated at baseline and after 3 years of GH replacement. Both groups responded similarly to GH treatment. Changes of clinical outcomes were mainly determined by their value at baseline. Onset of the disease in childhood or transition period did not appear to be a significant predictor of response in any of the clinical outcomes. Age at GHD diagnosis was a significant predictor for many outcomes at baseline, but disease onset did not appear as an independent predictor concerning changes after 3 years of GH treatment. The results suggest that GH replacement during the transition period should be considered independently of the onset of the deficiency.


  • A Longer Interval between Childhood and Adult Growth Hormone (GH) Replacement Is Associated with Lower Bone Mineral Density (BMD) in GH-Deficient (GHD) Adults — A KIMS (Pfizer International Metabolic Database) Analysis

    by Nicholas A Tritos, Amir H Hamrahian, Donna King, Susan L Greenspan, David M Cook, Peter J Jonsson, Michael P Wajnrajch, Maria Koltowska-Haggstrom, Beverly Mk Biller

    Article published by the Endocrine Society Article published by the Endocrine Society

  • Open Access

    Adaptation of the QoL-AGHDA scale for adults with growth hormone deficiency in four Slavic languages

    by Stephen P McKenna, Jeanette Wilburn, James Twiss, Sigrid R Crawford, Václav Hána, Malgorzata Karbownik-Lewinska, Vera Popovic, Mikulas Pura, Maria Koltowska-Häggström

    The Quality of Life in Adult Growth Hormone Deficiency Assessment (QoL-AGHDA) is a disease-specific quality of life measure specific to individuals who are growth hormone deficient. The present study describes the adaptation of the QoL-AGHDA for use in the following four Slavic languages; Czech, Polish, Serbian and Slovakian. The study involved three stages in each language; translation, cognitive debriefing and validation. The validation stage assessed internal consistency (Cronbach's alpha), reproducibility (test-retest reliability using Spearman's rank correlations), convergent and divergent validity (Correlations with the NHP) and known group validity. The QoL-AGHDA was successfully translated into the target languages with minimal problems. Cognitive debriefing interviewees (n = 15-18) found the measures easy to complete and identified few problems with the content. Internal consistency (Czech Republic = 0.91, Poland = 0.91, Serbia = 0.91 and Slovakia = 0.89) and reproducibility (Czech Republic = 0.91, Poland = 0.91, Serbia = 0.88 and Slovakia = 0.93) were good in all adaptations. Convergent and divergent validity and known group validity data were not available for Slovakia. The QoL-AGHDA correlated as expected with the NHP scales most relevant to GHD. The QoL-AGHDA was able to distinguish between participants based on a range of variables. The QoL-AGHDA was successfully adapted for use in the Czech Republic, Poland, Serbia and Slovakia. Further validation of the Slovakian version would be beneficial. The addition of these new language versions will prove valuable to multinational clinical trials and to clinical practice in the respective countries.


  • Open Access

    Discontinuation of Growth Hormone (GH) Treatment during the Transition Phase Is an Important Factor Determining the Phenotype of Young Adults with Nonidiopathic Childhood-Onset GH Deficiency

    by Maria Kołtowska-Häggström, Mitchell E. Geffner, Peter JönSson, John P. Monson, Roger Abs, VácLav HánA, Charlotte HöyBye, Hartmut A. Wollmann

    Context: Little is known about the impact of childhood-onset GH deficiency (GHD), in particular the duration of GH cessation during the transition phase, on adult phenotype. Objective: We investigated the association between the manifestations and management of GHD during childhood/adolescence and the clinical features of GHD in adulthood. Design/Setting/Patients/Intervention: Patients with reconfirmed childhood-onset GHD who resumed GH treatment as adults were identified from two sequential databases (n = 313). The cohort was followed up longitudinally from GH start in childhood to reinitiation of treatment in adulthood and 1 yr beyond. Analyses were performed in the total cohort and in subgroups of patients with idiopathic GHD (IGHD) and non-IGHD. The cohorts were stratified based on duration of GH cessation (short, ≤2 yr; long, >2 yr). Main Outcome Measures: Regimen of pediatric GH administration, duration of GH interruption, IGF-I sd score, lipid concentrations, and quality of life were measured. Results: Mean duration of GH interruption was 4.4 yr. IGF-I sd score in adulthood was related to severity of childhood GHD. In non-IGHD patients, a longer duration of GH interruption was associated with a worse lipid profile (P < 0.0001). Non-IGHD patients who gained more height during childhood GH treatment reported better quality of life than those who gained less height (P < 0.05). Conclusions: Pediatricians should tailor GH treatment, not only for its beneficial effect on growth but also for future health in adulthood. In adults with reconfirmed GHD, particularly those with non-IGHD, early recommencement of GH should be considered.


  • Open Access

    Deriving reference values and utilities for the QoL-AGHDA in adult GHD

    by J. J. V. Busschbach, B. H. R. Wolffenbuttel, L. Annemans, W. J. Meerding, M. Kołtowska-Häggström

    Quality of life (QoL) measures are important in growth hormone (GH) deficiency (GHD) in adults. Ideally, for use in health economics, QoL should be expressed in utilities. The aim of this study was to obtain reference values and utilities for QoL of GHD in adults in Belgium and the Netherlands. The study was conducted in three stages: (1) The Quality of Life-Assessment for Growth Hormone Deficiency in Adults (QoL-AGHDA) and the EQ-5D were administered in a representative sample of 6,875 individuals from the Belgian and 1,400 individuals from the general Dutch population. The EQ-5Dindex can be used to estimate utilities. Using a regression, utilities were predicted from the QoL-AGHDA. (2) QoL-AGHDA scores were obtained from 299 Belgian and 234 Dutch adult patients with GHD and no GH replacement. These scores were converted to utilities and compared the burden of disease with other patient groups. (3) To test the criterion validity, the ‘standard’ EQ-5Dindex was used in a subsample of 64 Dutch GHD patients and compared with the predicted utilities. We obtained data from 1,026 Belgian (response rate = 15%) and 1,038 Dutch respondents (response rate = 74%). The Belgian mean QoL-AGHDA value was 6.95 (90% range = 14.00), and the Dutch mean was 5.48 (range = 13.00). The R 2 of the regression model to predict the EQ-5Dindex was 0.360 (Belgium) and 0.482 (the Netherlands). We demonstrated a considerable burden of disease in GHD patients, comparable to patients with hypertension or with type II diabetes. The criterion validity was 0.407 (intraclass correlation, ICC). Interventions in GHD can now be evaluated more validly in Belgium and the Netherlands.


  • Assessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations

    by Maria Koltowska-Häggström, Anders F Mattsson, Stephen M Shalet

    Quality of life (QoL) has emerged as an important construct that has found numerous applications across healthcare-related fields, ranging from research and clinical evaluation of treatment effects to pharmacoeconomic evaluations and global healthcare policy. Impairment of QoL is one of the key clinical characteristics in adult GHD and has been extensively studied in the Pfizer International Metabolic Database (KIMS). We provide summarized evidence on GH treatment effects for both clinical and health economic applications based on the KIMS data. The primary focus is on those aspects of QoL research that cannot be investigated in the traditional clinical trial setting, such as specific patient subgroups, cross-country comparisons and long-term follow-up. First, the impact of age, gender, disease onset, primary aetiology, extent of hypopituitarism, previous radiotherapy and obesity on QoL before and during long-term GH replacement is discussed. Secondly, the studies on QoL in relation to country-specific normative values are reviewed. Finally, health economic data derived from KIMS including both burden of disease and utility assessment are evaluated. We conclude that the wide spectrum of analyses performed on the KIMS data allows for practical application of the results not only to research and clinical practice but also to health policy and global medical decision making.


    • 1 January 2009
      • Vol. 15  (3) , 203-9

    Quality of life and growth hormone deficiency in adult patients in clinical evaluation and health economic assessment.

    by Maria Kołtowska-Häggström

    Quality of life (QoL) has emerged as a construct that has found applications across healthcare-related fields. In clinical applications QoL is evaluated within a certain disease in patient populations and in individual patients, whereas pharmacoeconomics requires that QoL is expressed as a single summary score (a health status index)--most often utility index, which is capable of quantifying differences between diseases. Impairment of QoL in hypopituitary adult patients without growth hormone (GH) replacement therapy has been evident for a long time. The benefits of GH, as assessed by randomized clinical trials, remain controversial with some studies showing benefits and others refuting them. One of the studies based on the KIMS (Pfizer International Metabolic Database), showed that irrespectively of the degree of initial impairment, overall QoL during long-term GH treatment, improved dramatically in the first 12 months, with steady progress thereafter towards the country-specific population mean. Problems with memory and tiredness were the most serious burden for untreated patients, followed by tenseness, self-confidence and problems with socialising. With treatment these improved in the reverse order, normalising for the latter three. Another KIMS study examined QoL, measured by utility-weighted index (QoL-AGHDA(utility)). QoL-AGHDA(utility) in patients before GH treatment differed from the population values. The main improvement occurred during the first year of treatment; however, the patients' utilities remained during subsequent follow-up, different from those reported by the general population. Despite an observed impact of age, aetiology, disease-onset and co-morbidities on QoL-AGHDA(utility), all patients showed similar beneficial response to treatment.


  • Registries as a tool in evidence‐based medicine: example of KIMS (Pfizer International Metabolic Database)

    by Lia P. Gutiérrez, Maria Kołtowska‐Häggström, Peter J. Jönsson, Anders F. Mattsson, Dag Svensson, Björn Westberg, Anton Luger

    Purpose: To evaluate the value of a registry, set in ‘real‐life practice’, as a contribution to evidence‐based medicine and to estimate the impact of information collected in such a registry, on the up to date knowledge in growth hormone (GH)‐related disorders.Methods: Analysis of data collected prospectively for a pharmacoepidemiological registry—KIMS (Pfizer International Metabolic Database)—in assessing long‐term clinical and safety outcomes of GH treatment (Genotropin®) in patients with GH deficiency. The study was based on 11 374 treated (40 000 patient‐years of observation) and 263 untreated adult GH deficient patients from 30 countries, in whom background characteristics, clinical values such as lipids and body composition, quality of life (QoL) and GH dosage as well as safety profile were evaluated. Citation analysis for the published papers was also performed.Results: The study depicts the clinical picture of adult patients with GH deficiency managed in current clinical settings. It confirms the features previously detected such as increased cardiovascular risk, mostly dyslipidemia and abnormal body composition as well as impaired QoL. There was considerable heterogeneity of conditions resulting in GH deficiency. The large database also enabled study of rare causes of the condition. The 31 out of 36 KIMS papers were cited 544 times, in 125 different journals.Conclusions: These findings and the further insight into the response to GH replacement therapy show that the registry methodology is valuable for filling the gaps of information in evidence‐based medicine that cannot be addressed by clinical trials. Copyright © 2007 John Wiley & Sons, Ltd.